Biotech News

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Sensei Biotherapeutics (SNSE)Sensei Biotherapeutics2026-05-15 11:30 ESTEarnings

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results

Related news

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is an immuno-oncology company focused on activating the immune system against cancer. Its platform aims to create differentiated cancer treatments through immune modulation.

Recent company news

SNSESensei Biotherapeutics2026-05-15 11:30 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-05-05 11:30 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

SNSESensei Biotherapeutics2026-04-09 11:30 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-03-30 11:30 EST

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-03-17 10:00 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: 13.85 USD
Market cap: 21.6M USD
Exchange: NYSE
Sector: Biopharma
Location: United States